Significance of perioperative infection in survival of patients with ovarian cancer.
OBJECTIVE
Perioperative infectious diseases comprise some of the most common causes of surgical mortality in women with ovarian cancer. This study was aimed to evaluate the significance of perioperative infections in survival of patients with ovarian cancer.


METHODS
Patients who underwent primary cytoreductive surgery were included in the analysis (n = 276). The enumeration and speciation of pathogens, antimicrobial agents used, and sensitivity assay results were culled from medical records and correlated to clinicopathologic demographics and survival outcomes. Perioperative infection was determined as a positive microbiology result obtained within a 6-week postoperative period.


RESULTS
The incidence of perioperative infection was 15.9% (common sites: urinary tract, 57.3%, and surgical wound, 21.4%). Commonly isolated pathogens were Enterococcus species (22.4%) and Escherichia coli (19.4%) in urinary tract infection, and Bacteroides fragilis, E. coli, and Klebsiella pneumoniae (all, 16%) in surgical wound infection. Imipenem represents one of the least resistant antimicrobial agents commonly seen in urinary tract and surgical wound infections in our institution. Perioperative infection was associated with diabetes, serous histology, lymph node metastasis, bowel resection, decreased bicarbonate, and elevated serum urea nitrogen in multivariate analysis. Perioperative infections were associated with increased surgical mortality, delay in chemotherapy treatment, decreased chemotherapy response, shorter progression-free survival (median time, 8.4 vs 17.6 months; P < 0.001), and decreased overall survival (29.0 vs 51.8 months; P = 0.011). Multivariate analysis showed that perioperative infections other than urinary tract infection remained a significant risk factor for decreased survival (progression-free survival, P = 0.02; and overall survival, P = 0.019).


CONCLUSIONS
Perioperative infectious disease comprises an independent risk factor for survival of patients with ovarian cancer.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles County Medical Center, Los Angeles, CA 90031, USA. koji.matsuo@gmail.com
Koji
K
Matsuo
Christina P
CP
Prather
Edward H
EH
Ahn
Michele L
ML
Eno
Katherine E
KE
Tierney
Annie A
AA
Yessaian
Dwight D
DD
Im
Neil B
NB
Rosenshein
Lynda D
LD
Roman
D019540:Area Under Curve; D001441:Bacteroides fragilis / Q000302:isolation & purification; D015142:Baltimore; D018284:Cystadenocarcinoma, Serous / Q000150:complications / Q000401:mortality / Q000601:surgery*; D018572:Disease-Free Survival; D016983:Enterococcus / Q000302:isolation & purification; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D006801:Humans; D007711:Klebsiella pneumoniae / Q000302:isolation & purification; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications / Q000401:mortality / Q000601:surgery*; D059035:Perioperative Period; D012044:Regression Analysis; D012307:Risk Factors; D013530:Surgical Wound Infection / Q000401:mortality*; D016019:Survival Analysis; D014552:Urinary Tract Infections / Q000150:complications*